ACADIA PHARMACEUTICALS INC. (ACAD) Current Ratio
- Current ratio · latest quarter: Value 3.39×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 3.39× | Current assets / current liabilities. $1.22B ÷ $361.44M ≈ 3.39× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 1.22B USD | Assets, Current |
| Current obligations | 361.44M USD | Liabilities, Current |
| Cash and equivalents | 384.99M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 571.49M USD | Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current |
| Customer receivables | 150.64M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | 108.67M USD | Inventory, Net |
| Payables | 44.57M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) | Long-term Debt, Current Maturities |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.22B | $361.44M | $384.99M | $571.49M | $150.64M | $108.67M | $44.57M | (m) | 3.39× |
| 2026-03-31 | $1.10B | $305.52M | $282.21M | $569.25M | $135.35M | $112.29M | $12.25M | (m) | 3.59× |
| 2025-12-31 | $1.06B | $277.11M | $177.69M | $641.99M | $121.46M | $111.37M | $10.90M | (m) | 3.83× |
| 2025-09-30 | $1.08B | $356.58M | $258.00M | $589.02M | $115.85M | $105.98M | $21.75M | (m) | 3.02× |
| 2025-06-30 | $960.55M | $330.02M | $253.64M | $508.36M | $107.50M | $110.53M | $20.10M | (m) | 2.91× |
| 2025-03-31 | $870.94M | $302.53M | $217.70M | $463.88M | $105.74M | $102.97M | $18.09M | (m) | 2.88× |
| 2024-12-31 | $938.32M | $394.87M | $319.59M | $436.40M | $98.74M | $91.69M | $16.19M | (m) | 2.38× |
| 2024-09-30 | $788.28M | $343.94M | $155.15M | $410.18M | $98.21M | $86.74M | $19.08M | (m) | 2.29× |
| 2024-06-30 | $728.92M | $337.85M | $177.13M | $323.81M | $103.70M | $86.07M | $19.88M | (m) | 2.16× |
| 2024-03-31 | $675.30M | $330.60M | $204.75M | $265.77M | $94.70M | $66.64M | $19.33M | (m) | 2.04× |
| 2023-12-31 | $616.13M | $254.25M | $188.66M | $250.21M | $98.27M | $40.45M | $17.54M | (m) | 2.42× |
| 2023-09-30 | $499.17M | $209.60M | $98.19M | $247.73M | $92.80M | $25.40M | $12.31M | (m) | 2.38× |
| 2023-06-30 | $492.63M | $187.94M | $107.94M | $267.44M | $81.85M | $14.12M | $18.81M | (m) | 2.62× |
| 2023-03-31 | $502.85M | $224.30M | $290.89M | $111.98M | $65.92M | $11.02M | $17.42M | (m) | 2.24× |
| 2022-12-31 | $507.94M | $125.63M | $114.85M | $301.98M | $62.20M | $11.56M | $12.75M | (m) | 4.04× |
| 2022-09-30 | $521.55M | $116.57M | $154.84M | $281.74M | $55.73M | $11.84M | $10.01M | (m) | 4.47× |
| 2022-06-30 | $532.52M | $117.68M | $139.83M | $296.52M | $67.95M | $12.53M | $11.85M | (m) | 4.53× |
| 2022-03-31 | $542.22M | $119.60M | $204.92M | $241.06M | $62.71M | $13.21M | $10.77M | (m) | 4.53× |
| 2021-12-31 | $617.82M | $96.07M | $147.44M | $373.27M | $64.37M | $14.10M | $6.88M | (m) | 6.43× |
| 2021-09-30 | $640.92M | $88.22M | $94.64M | $445.65M | $60.70M | $14.34M | $7.72M | (m) | 7.27× |
| 2021-06-30 | $645.73M | $95.33M | $266.96M | $289.96M | $51.37M | $10.79M | $9.06M | (m) | 6.77× |
| 2021-03-31 | $673.98M | $109.37M | $304.49M | $273.28M | $56.83M | $10.31M | $8.85M | (m) | 6.16× |
| 2020-12-31 | $717.62M | $105.97M | $326.03M | $305.93M | $48.25M | $9.68M | $8.49M | (m) | 6.77× |
| 2020-09-30 | $730.21M | $91.86M | $452.35M | $192.09M | $46.34M | $7.98M | $3.47M | (m) | 7.95× |
| 2020-06-30 | $735.74M | $86.42M | $310.44M | $348.11M | $43.78M | $6.21M | $6.47M | (m) | 8.51× |
| 2020-03-31 | $724.42M | $99.74M | $173.06M | $478.35M | $41.64M | $6.32M | $6.62M | (m) | 7.26× |
| 2019-12-31 | $760.25M | $74.83M | $189.68M | $507.75M | $35.78M | $6.34M | $7.22M | (m) | 10.16× |
| 2019-09-30 | $742.33M | $67.74M | $385.47M | $298.37M | $30.80M | $4.85M | $3.44M | (m) | 10.96× |
| 2019-06-30 | $436.94M | $63.81M | $74.43M | $307.45M | $31.78M | $3.82M | $4.65M | (m) | 6.85× |
| 2019-03-31 | $476.41M | $74.98M | $97.56M | $316.77M | $29.96M | $4.57M | $3.27M | (m) | 6.35× |
| 2018-12-31 | $526.11M | $59.56M | $134.76M | $338.76M | $26.09M | $4.07M | $3.17M | (m) | 8.83× |
| 2018-09-30 | $254.12M | $41.81M | $63.90M | $150.24M | $19.96M | $4.35M | $2.96M | (m) | 6.08× |
| 2018-06-30 | $301.10M | $49.21M | $74.18M | $182.67M | $25.70M | $4.74M | $3.33M | (m) | 6.12× |
| 2018-03-31 | $340.01M | $46.09M | $116.33M | $181.74M | $22.45M | $5.58M | $3.00M | (m) | 7.38× |
| 2017-12-31 | $373.48M | $49.03M | $69.42M | $271.92M | $17.34M | $5.25M | $8.79M | (m) | 7.62× |
| 2017-09-30 | $401.97M | $36.14M | $112.62M | $254.01M | $14.22M | $5.54M | $2.96M | (m) | 11.12× |
| 2017-06-30 | $443.75M | $40.91M | $143.79M | $273.53M | $11.59M | $6.00M | $3.59M | (m) | 10.85× |
| 2017-03-31 | $489.75M | $45.27M | $157.38M | $312.10M | $7.66M | $3.88M | $2.17M | (m) | 10.82× |
| 2016-12-31 | $547.90M | $42.59M | $163.62M | $365.42M | $5.90M | $4.17M | $3.91M | (m) | 12.87× |
| 2016-09-30 | $603.49M | $39.15M | $153.68M | $435.18M | $3.84M | $4.30M | $2.83M | (m) | 15.42× |
| 2016-06-30 | $423.90M | $29.02M | $131.77M | $280.78M | $293.00K | $2.87M | $1.02M | (m) | 14.61× |
| 2016-03-31 | $462.35M | $21.12M | $175.22M | $282.02M | (m) | (m) | $1.31M | (m) | 21.89× |
| 2015-12-31 | $218.99M | $21.90M | $102.14M | $112.99M | (m) | (m) | $1.67M | (m) | 10.00× |
| 2015-09-30 | $242.85M | $17.73M | $70.80M | $169.89M | (m) | (m) | $2.20M | (m) | 13.69× |
| 2015-06-30 | $273.39M | $19.38M | $93.21M | $177.56M | (m) | (m) | $2.92M | (m) | 14.11× |
| 2015-03-31 | $299.90M | $16.65M | $76.42M | $221.47M | (m) | (m) | $2.52M | (m) | 18.01× |
| 2014-12-31 | $324.62M | $15.83M | $61.85M | $260.63M | (m) | (m) | $2.02M | (m) | 20.50× |
| 2014-09-30 | $341.06M | $11.25M | $36.37M | $301.43M | (m) | (m) | $1.11M | (m) | 30.31× |
| 2014-06-30 | $358.85M | $9.34M | $13.70M | $340.75M | (m) | (m) | $1.10M | (m) | 38.43× |
| 2014-03-31 | $372.82M | $8.03M | $96.45M | $272.83M | (m) | (m) | $1.56M | (m) | 46.41× |
| 2013-12-31 | $188.36M | $6.98M | $11.71M | $174.08M | (m) | (m) | $372.00K | (m) | 26.99× |
| 2013-09-30 | $198.68M | $7.87M | $11.80M | $184.38M | (m) | (m) | $1.12M | (m) | 25.24× |
| 2013-06-30 | $206.76M | $7.78M | $24.25M | $181.20M | (m) | (m) | $1.18M | (m) | 26.59× |
| 2013-03-31 | $102.98M | $5.70M | $18.44M | $83.03M | (m) | (m) | $1.40M | (m) | 18.08× |
| 2012-12-31 | $108.55M | $5.95M | $57.90M | $50.07M | (m) | (m) | $1.38M | (m) | 18.25× |
| 2012-09-30 | $23.68M | $6.09M | $8.02M | $15.04M | (m) | (m) | $1.13M | (m) | 3.89× |
| 2012-06-30 | $21.77M | $6.76M | $9.21M | $12.14M | (m) | (m) | $757.00K | (m) | 3.22× |
| 2012-03-31 | $26.39M | $6.43M | $5.56M | $20.37M | (m) | (m) | $1.03M | $22.00K | 4.10× |
| 2011-12-31 | $31.95M | $6.17M | $6.89M | $24.16M | (m) | (m) | $1.96M | (m) | 5.18× |
| 2011-09-30 | $36.76M | $6.41M | $8.32M | $27.83M | (m) | (m) | $1.26M | $37.00K | 5.74× |
| 2011-06-30 | $41.02M | $5.95M | $8.02M | $32.34M | (m) | (m) | $1.14M | $40.00K | 6.90× |
| 2010-12-31 | $37.85M | $5.96M | $6.85M | $30.24M | (m) | (m) | $1.97M | $78.00K | 6.35× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |